GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » Cyclically Adjusted PB Ratio

Gilead Sciences (BSP:GILD34) Cyclically Adjusted PB Ratio : 3.85 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Gilead Sciences's current share price is R$168.96. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$43.83. Gilead Sciences's Cyclically Adjusted PB Ratio for today is 3.85.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:GILD34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.68   Med: 7.61   Max: 28.67
Current: 3.68

During the past years, Gilead Sciences's highest Cyclically Adjusted PB Ratio was 28.67. The lowest was 3.68. And the median was 7.61.

BSP:GILD34's Cyclically Adjusted PB Ratio is ranked worse than
76.26% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.8 vs BSP:GILD34: 3.68

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share data for the three months ended in Mar. 2024 was R$34.853. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$43.83 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PB Ratio Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.83 4.71 5.04 5.27 4.59

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.95 4.50 4.28 4.59 4.13

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.



Gilead Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Gilead Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=168.96/43.83
=3.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=34.853/129.4194*129.4194
=34.853

Current CPI (Mar. 2024) = 129.4194.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 11.788 100.560 15.171
201409 10.477 100.428 13.502
201412 13.594 99.070 17.758
201503 18.270 99.621 23.735
201506 17.203 100.684 22.113
201509 23.454 100.392 30.236
201512 25.291 99.792 32.800
201603 18.378 100.470 23.673
201606 19.980 101.688 25.429
201609 20.755 101.861 26.370
201612 24.178 101.863 30.719
201703 24.456 102.862 30.770
201706 28.610 103.349 35.827
201709 29.773 104.136 37.002
201712 25.748 104.011 32.038
201803 25.968 105.290 31.919
201806 31.530 106.317 38.381
201809 36.294 106.507 44.102
201812 32.392 105.998 39.549
201903 33.088 107.251 39.927
201906 34.427 108.070 41.228
201909 33.522 108.329 40.048
201912 36.514 108.420 43.586
202003 42.992 108.902 51.092
202006 37.293 108.767 44.374
202009 37.591 109.815 44.302
202012 37.338 109.897 43.971
202103 42.582 111.754 49.313
202106 39.504 114.631 44.600
202109 45.155 115.734 50.494
202112 47.505 117.630 52.266
202203 39.508 121.301 42.152
202206 40.728 125.017 42.162
202209 44.075 125.227 45.551
202212 44.672 125.222 46.169
202303 43.816 127.348 44.529
202306 41.175 128.729 41.396
202309 44.185 129.860 44.035
202312 44.893 129.419 44.893
202403 34.853 129.419 34.853

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (BSP:GILD34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Gilead Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BSP:GILD34) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BSP:GILD34) Headlines

No Headlines